文献速递神经肿瘤

CD147与胶质瘤:一项Meta分析

CD147 and glioma: a meta-analysis.
PubMed 文献 · J Neurooncol · 2017-05-30

该Meta分析纳入19项研究共1806例胶质瘤患者,系统评价CD147表达与临床病理特征的关系。CD147过表达与较差总生存(HR=2.211,P<0.0001)、较高复发风险(HR=2.20,P=0.0025)及较低5年生存率(OR 0.12;95%CI 0.08-0.19;P<0.00001)相关,并与肿瘤分级、肿瘤大小及MMP2/MMP9表达显著相关。

要点

  • CD147过表达与胶质瘤患者较差总生存(HR=2.211,P<0.0001)和较高复发风险(HR=2.20,P=0.0025)相关。
  • CD147过表达者5年生存率较低(OR 0.12;95%CI 0.08-0.19;P<0.00001)。
  • CD147表达与肿瘤分级III-IV vs I-II(OR 5.88,95%CI 4.15-8.34)、大肿瘤 vs 小肿瘤(OR 1.58,95%CI 1.04-2.40)及MMP2/MMP9相关。

核心结论

  • CD147表达可能是预测胶质瘤患者较差总生存和无复发生存的潜在预后生物标志物,并可能影响5年生存率。
  • CD147表达与胶质瘤患者不良临床特征密切相关。

研究设计与样本

  • Meta分析,检索PubMed(1966-2016)、EMBASE(1980-2016)、Cochrane Library(1996-2016)、Web of Science(1945-2016)、中国知网(1982-2016)和万方数据库(1988-2016)。
  • 采用纽卡斯尔-渥太华量表进行文献质量评价,使用Revman 5.3和Stata 14.0进行分析。
  • 共纳入19项研究、1806例胶质瘤患者。

主要发现

  • CD147过表达者总生存较差(HR=2.211,P<0.0001),复发风险较高(HR=2.20,P=0.0025),5年生存率较低(OR 0.12;95%CI 0.08-0.19;P<0.00001)。
  • 胶质瘤组织 vs 非癌脑组织中CD147表达有显著差异(OR 20.42;95%CI 13.94-29.91;P<0.00001)。
  • 肿瘤分级III-IV vs I-II的CD147表达有显著差异(OR 5.88,95%CI 4.15-8.34;P<0.00001)。
  • 大肿瘤 vs 小肿瘤的CD147表达有显著差异(OR 1.58,95%CI 1.04-2.40;P=0.03)。
  • CD147与MMP2(OR 39.11,95%CI 11.47-133.34;P<0.00001)和MMP9(OR 13.35,95%CI 4.67-38.18;P<0.00001)表达显著相关。

关键数值与推荐

  • 年龄(年轻 vs 年老)与CD147表达无关(P=0.89)。
  • 性别(女性 vs 男性)与CD147表达无关(P=0.57)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gliomas are the most common primary brain tumors. This meta-analysis aimed to systematically evaluate the relationship between CD147 expression in tissues and the clinicopathological features of patients with glioma. We searched PubMed (1966-2016), EMBASE (1980-2016), Cochrane Library (1996-2016), Web of Science (1945-2016), China National Knowledge Infrastructure (1982-2016), and Wan Fang databases (1988-2016). Quality assessment of the literature was performed using the Newcastle-Ottawa Scale, with Revman 5.3 and Stata 14.0 for analysis. In total, 1806 glioma patients from 19 studies were included, and patients with CD147 overexpression had poorer overall survival [hazard ratio (HR) = 2.211, P < 0.0001], a higher risk of recurrence (HR = 2.20, P = 0.0025), and a lower 5-year survival rate [odds ratio (OR) 0.12; 95% CI 0.08-0.19; P < 0.00001]. We observed significant differences in CD147 expression when comparing glioma tissues versus non-cancerous brain tissues (OR 20.42; 95% CI 13.94-29.91; P < 0.00001), tumor grades III-IV versus grades I-II (OR 5.88, 95% CI 4.15-8.34; P < 0.00001), and large versus small tumors (OR 1.58, 95% CI 1.04-2.40; P = 0.03). We also observed a significant correlation with matrix metalloproteinase (MMP) 2 (OR 39.11, 95% CI 11.47-133.34; P < 0.00001) and MMP9 (OR 13.35, 95% CI 4.67-38.18; P < 0.00001). CD147 expression did not differ based on patient's age (young vs. old, P = 0.89) or gender (female vs. male, P = 0.57). CD147 expression may be a potential prognostic biomarker for poorer overall and relapse-free survival, and may affect the 5-year survival rate in glioma patients. CD147 expression is also closely correlated with poor clinical characteristics in glioma patients.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Li H, Xi Z, Dai X, et al. CD147 and glioma: a meta-analysis. J Neurooncol. 2017. PMID: 28560663. doi:10.1007/s11060-017-2499-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。